Search

Displaying results 8471 - 8480 of 10000 in total
  1. Drug

    Inarigivir

    go.drugbank.com/drugs/DB15062
    Investigational

    Inarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis

  2. Drug

    Tizaterkib

    go.drugbank.com/drugs/DB21296
    Investigational

    Tizaterkib is under investigation in clinical trial NCT04305249 (Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological … The usage of the INN stem '-terkib' in the name indicates that Tizaterkib is a extracellular signal-regulated kinase (ERK) inhibitor.

  3. Drug

    Tofimilast

    go.drugbank.com/drugs/DB11681
    Investigational

    Tofimilast has been used in trials studying the treatment of Asthma and Pulmonary Disease, Chronic Obstructive.

  4. Drug

    Tofogliflozin

    go.drugbank.com/drugs/DB11824
    Investigational

    Tofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2.

  5. Drug

    IQP-0528

    go.drugbank.com/drugs/DB14888
    Investigational

    IQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).

  6. Drug

    Rivenprost

    go.drugbank.com/drugs/DB16315
    Investigational

    Rivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).

  7. Drug

    DYN-101

    go.drugbank.com/drugs/DB17921
    Investigational

    DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.

  8. Drug

    Suvodirsen

    go.drugbank.com/drugs/DB17940
    Investigational

    Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.

  9. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.

  10. Drug

    Leflutrozole

    go.drugbank.com/drugs/DB19047
    Investigational

    Leflutrozole is under investigation in clinical trial NCT02908074 (A 6 Month Safety Extension Study of MBGS205).